Alzheimer\'s disease (AD) is a neurodegenerative disorder pathologically characterised by deposits of *β*-amyloid (A*β*) in senile plaques, intracellular neurofibrillary tangles comprising hyperphosphorylated tau, synaptic dysfunction and neuronal death, some or all of which are believed to cause the cognitive and behavioural deficits that typify this disease. It is now widely recognised that neuroinflammation is a prominent feature of AD brain, with inflammatory responses playing a significant role in modulating disease progression.^[@bib1]^

Prolonged and widespread activation of microglia and astrocytes are apparent in AD brain, in which the severity of glial activation correlates with the extent of brain atrophy^[@bib2]^ and cognitive decline.^[@bib3]^ The majority of transgenic rodent models of AD also exhibit substantial reactive gliosis and accumulation of activated astrocytes in affected brain regions.^[@bib4],\ [@bib5]^ These features are often observed before the appearance of plaque and tangle pathology,^[@bib6],\ [@bib7]^ and the degree of inflammatory cell activation correlates with pathology development and neuronal death in mouse models of AD.^[@bib6],\ [@bib8]^

The role of microglia in the development and/or progression of AD is somewhat controversial. Phagocytosis of A*β* by microglia is believed to be a protective mechanism,^[@bib9]^ at least in younger animals;^[@bib10]^ however, neuronal loss also results from increased pro-inflammatory cytokine production by microglia in models of AD.^[@bib10]^ In addition to the influence of microglia, an important role of astrocytes in regulating A*β*-induced neuronal death has recently been illustrated.^[@bib11]^

Both astrocytes and microglia release a myriad of pro- and anti- inflammatory cytokines, including interleukins (ILs), interferons (IFNs) and tumour necrosis factors (TNFs), as well as chemokines, a family of small pro-inflammatory cytokines that includes macrophage inflammatory proteins and monocyte chemoattractant proteins.^[@bib12]^ Receptor binding of cytokines stimulates a variety of intracellular signalling pathways that have been implicated in AD, including the activation of protein kinase C, c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38/MAPK), PI3 kinase, extracellular signalling-related kinase (ERK), as well as activation of caspase-1 and -3.^[@bib13],\ [@bib14]^

Caspases are closely associated with induction of the apoptotic cascade, and activation of caspase-3 is both necessary and sufficient to trigger apoptotic cell death in response to elevated A*β* in AD.^[@bib15]^ In addition, A*β*-induced caspase-3 activation causes abnormal processing of the microtubule-associated protein tau in models of AD.^[@bib16],\ [@bib17]^ Cleavage of tau by caspase-3 at Asp421 generates a truncated form that aggregates more rapidly, and to a greater extent, than full-length tau,^[@bib18],\ [@bib19]^ and caspase-cleaved tau fragments directly reduce neuronal viability.^[@bib16]^ Aberrant tau phosphorylation in response to elevated A*β* also contributes to tau aggregation and fibrillisation in AD.^[@bib20]^ Putative tau kinases that phosphorylate tau in response to A*β* include cyclin-dependent kinase-5, glycogen synthase kinase-3*β*, p38/MAPK, JNK-1 and ERK,^[@bib21],\ [@bib22]^ several of which are activated by increased production or release of cytokines.^[@bib13]^

We have shown previously that the neuroprotective agent, minocycline, reduces tau phosphorylation and proteolysis in both A*β*-treated primary cortical cultures and also in htau mice, which progressively accumulate hyperphosphorylated aggregated tau and show significant neuronal loss in the cortex and hippocampus in the absence of elevated A*β*.^[@bib17]^ In htau mice, the impact of minocycline on tau pathology was not associated with tau kinase inhibition,^[@bib17]^ but correlated with reductions in astrocytosis and in the CNS burden of pro-inflammatory factors.^[@bib6]^ Indeed, the cortical amounts of individual inflammatory cytokines correlated strongly with phosphorylated tau load.^[@bib6]^ Here, we have investigated the role of astrocytes in A*β*-induced tau phosphorylation and cleavage, as well as determining the influence of astrocytes in mediating A*β*-induced neuronal death.

Results
=======

Astrocytes accelerate A*β*-induced neurotoxicity
------------------------------------------------

We first compared primary cortical cultures in which neurons were either cultured alone (neuronal cultures) or were in co-culture with astrocytes (mixed cultures). Immunolabelling with cell-type-specific antibodies identified constituent cells in the cultures and revealed an absence of glia in neuronal cultures. Mixed cultures were predominantly neuronal, containing 4.4±0.4% astrocytes and a negligible amount of microglia (\<0.01%) after 7 days *in vitro* (DIV).

To determine whether or not astrocytes influence A*β*-induced neurotoxicity, mixed and neuronal cultures were treated with 10 *μ*M soluble oligomeric A*β* and lactate dehydrogenase (LDH) release was used to measure cell viability. A*β* treatment of mixed cultures, but not neuronal cultures, resulted in a statistically significant increase in LDH release at both 48 and 72 h ([Figures 1a and b](#fig1){ref-type="fig"}; *P*\<0.001). In contrast, significantly increased LDH release was only observed in neuronal cultures following a 72 h treatment with A*β* ([Figure 1b](#fig1){ref-type="fig"}; *P*\<0.01). A*β* treatment did not cause increased release of LDH from cultured astrocytes ([Figure 1c](#fig1){ref-type="fig"}), indicating that the presence of astrocytes significantly accelerates A*β*-induced neuronal death.

To confirm that neurons, and not astrocytes, are susceptible to A*β* toxicity in mixed culture, a fixable dead cell staining kit was used in conjunction with immunolabelling of astrocytes ([Figure 1d](#fig1){ref-type="fig"}). As expected, this method revealed a proportion of dead cells following A*β* treatment. However, glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes were not labelled by the dead cell dye. Furthermore, the nuclei of astrocytes were not fragmented or condensed, unlike many of the surrounding neurons ([Figure 2d](#fig2){ref-type="fig"}, white arrows). In further support of this finding, no alteration in the abundance of astrocytes was apparent in mixed cultures following A*β* treatment (Supplementary Figure 1). These results support those from the LDH assays and conclusively show that in mixed cell cultures, only neurons are susceptible to A*β*-induced toxicity.

To determine if astrocytic inflammatory responses are involved in the acceleration of A*β*-induced neurotoxicity, cultures were pretreated with the anti-inflammatory agent minocycline. LDH release was not significantly affected by minocycline alone in any of the cultures. Pretreatment of mixed, but not neuronal cultures with minocycline resulted in reduced LDH release from cultures treated with A*β* for 48 or 72 h ([Figures 1a and b](#fig1){ref-type="fig"}; *P*\<0.05 and *P*\<0.001, respectively). This finding suggests that minocycline may reduce A*β*-induced neuronal death by suppressing the inflammatory response of astrocytes.

A*β* induces morphological changes in astrocytes
------------------------------------------------

Astrocytes are highly dynamic cells that exhibit morphological changes depending on their cellular environment.^[@bib23],\ [@bib24]^ In primary culture, the morphology of astrocytes is considered a reliable marker of their activation state.^[@bib25]^ Therefore, we next examined astrocyte morphology in response to A*β* and minocycline in mixed cultures. Under control conditions, and following treatment with minocycline alone, astrocytes appeared as stellate process-bearing cells ([Figures 2a and b](#fig2){ref-type="fig"}), in line with previous reports.^[@bib24]^ Following exposure to A*β*, there were clear and robust alterations in astrocyte morphology with the appearance of convoluted processes and terminal swellings ([Figure 2c](#fig2){ref-type="fig"}, single arrows). Such changes are believed to represent characteristics of astrocyte activation in culture.^[@bib25],\ [@bib26]^ These alterations are not indicative of dystrophic astrocytes as A*β*-treated astrocytes do not label with the dead cell dye ([Figure 1d](#fig1){ref-type="fig"}). Pretreatment with minocycline before A*β* prevented these A*β*-induced morphological changes in mixed cultures ([Figure 2d](#fig2){ref-type="fig"}).

In contrast, following A*β* treatment, neurons displayed condensed and fragmented neuronal nuclei (double arrows, [Figure 2c](#fig2){ref-type="fig"}) and a disrupted tubulin cytoskeleton ([Figure 2c](#fig2){ref-type="fig"}). These results add further support to our finding that neurons, rather than astrocytes, are susceptible to A*β* toxicity in mixed culture. Pretreatment of mixed cultures with minocycline before the addition of A*β* reduced these markers of neuronal death ([Figure 2d](#fig2){ref-type="fig"}).

These results suggest that astrocytes are activated in response to A*β*, which is an event closely associated with A*β*-induced neuronal death. Furthermore, minocycline-mediated neuroprotection from A*β* toxicity appears to be associated with the inhibition of astrocyte activation.

A soluble factor secreted from astrocytes mediates A*β*-induced neuronal death
------------------------------------------------------------------------------

Astrocytes may mediate neuronal responses both by direct membrane interactions^[@bib27]^ and by the release of factors that bind to neuronal receptors.^[@bib11]^ To investigate the mechanism underlying the astrocyte-mediated acceleration of A*β*-induced neuronal death, we treated primary cortical astrocyte-enriched cultures with A*β* for 48 h, a treatment that is not toxic to these cells ([Figure 1c](#fig1){ref-type="fig"}). Addition of conditioned medium from A*β*-treated astrocytes to cultured neurons resulted in increased LDH release ([Figure 3a](#fig3){ref-type="fig"}). As a control, A*β* was incubated in astrocyte culture medium, in the absence of cells, for 48 h, and application of this medium to neurons did not affect cell viability ([Figure 3b](#fig3){ref-type="fig"}). These results show that a component of the astrocyte-conditioned medium mediates neuronal death. ELISA measurement of A*β* in conditioned medium revealed that the amount of A*β* reduced from 10 to 1.08±0.06 *μ*M after 48 h incubation with primary astrocyte cultures. As 1 *μ*M A*β* is insufficient to induce neuronal death in these cultures, we conclude that a soluble factor released from astrocytes is important for A*β*-induced neurotoxicity. Pretreatment of astrocyte-enriched cultures with minocycline before A*β* application significantly reduced neuronal death in this model system ([Figure 3b](#fig3){ref-type="fig"}), suggesting that the neurotoxic astrocyte-derived soluble factor(s) released in response to A*β* may be an inflammatory mediator.

Astrocytes increase A*β*-induced caspase-3 activity
---------------------------------------------------

The finding that astrocytes accelerate A*β*-induced neuronal toxicity led us to investigate whether caspase-3 activity was influenced by astrocytes, as increased caspase-3 activity is associated with A*β*-induced neurotoxicity.^[@bib15],\ [@bib16],\ [@bib17]^ Furthermore, we have shown that minocycline inhibits caspase-3 activation in both primary cortical cultures and in htau mice,^[@bib17]^ the former closely associated with protection from A*β*-induced neurotoxicity. To investigate if astrocytes influence caspase-3 activity, we analysed cell lysates from A*β*- and/or minocycline-treated mixed and neuronal cultures on western blots ([Figure 4](#fig4){ref-type="fig"}).

Caspase-3 is activated by cleavage, generating fragments of approximately 17 and 19 kDa from the full-length (35 kDa) protein. We therefore measured caspase-3 activity using an antibody against cleaved caspase-3 ([Figure 4a](#fig4){ref-type="fig"}). Treatment of both mixed and neuronal cultures with A*β* for 48 h significantly increased the amount of cleaved caspase-3 present in cell lysates, when compared with those from vehicle-treated cells (*P*\<0.001 and *P*\<0.01, respectively). The activation of caspase-3 by A*β* was significantly enhanced in mixed cultures when compared with neuronal cultures (*P*\<0.05), indicating that astrocytes exacerbate A*β*-induced caspase-3 activation, and this is likely related to the impact of astrocytes in mediating A*β*-induced neuronal death. Pretreatment of both mixed and neuronal cultures with minocycline reduced the A*β*-induced accumulation of cleaved caspase-3 ([Figure 4b](#fig4){ref-type="fig"}; *P*\<0.01 and *P*\<0.05, respectively). This suggests that while astrocytic inflammatory responses may exacerbate caspase-3 activation in response to A*β*, both neurons and astrocytes are targeted by minocycline to reduce caspase-3 activation.

Astrocytes exacerbate A*β*-mediated tau truncation
--------------------------------------------------

The truncation of tau by caspase-3 is believed to be an important event during the development of tau pathology in AD, with caspase-3-cleaved tau more prone to aggregation than full-length tau.^[@bib18],\ [@bib19]^ A*β* has previously been shown to induce the generation of caspase-3-cleaved tau species in primary cortical cultures,^[@bib17]^ an event associated with neuronal death.^[@bib19],\ [@bib28]^

Therefore, cell lysates from mixed and neuronal cultures were assessed for caspase-cleaved tau by western blotting using an antibody that specifically detects tau that has been cleaved at Asp421 ([Figures 5a and b](#fig5){ref-type="fig"}). In both types of control cultures, small amounts of caspase-3-cleaved tau were detected at approximately 50 kDa, in line with our previous findings.^[@bib17]^ A*β* treatment significantly increased the amount of cleaved tau present in both mixed and neuronal cultures ([Figure 5b](#fig5){ref-type="fig"}; *P*\<0.001 and *P*\<0.01, respectively); however, significantly more caspase-3-cleaved tau was apparent following A*β* treatment of mixed cultures when compared with neuronal cultures (*P*\<0.05). Cultured astrocytes contain only trace amounts of tau ([Figure 5c](#fig5){ref-type="fig"}), suggesting that the tau measured in the mixed cultured is of neuronal origin, and that the presence of astrocytes significantly potentiates the generation of caspase-cleaved tau in neurons in response to A*β* ([Figures 5a and b](#fig5){ref-type="fig"}). Pretreatment of mixed, but not neuronal, cultures with minocycline significantly reduced the amount of caspase-3-cleaved tau species generated in response to A*β* treatment (*P*\<0.01), again suggesting that astrocytic inflammatory responses may have a role in the A*β*-induced cell signalling that leads to caspase activation and tau cleavage.

Astrocytes are necessary for A*β*-induced tau phosphorylation
-------------------------------------------------------------

Truncation of tau is closely associated with its phosphorylation,^[@bib29]^ and A*β*-induced tau phosphorylation is widely regarded as an important event in AD.^[@bib22]^ To determine if astrocytes mediate A*β*-induced tau phosphorylation in our model system, cell lysates from A*β*-treated mixed and neuronal cultures were assessed by western blotting. Blots were probed with antibodies against total tau, and tau phosphorylated at serine (Ser) 396/404 (PHF1) and Ser202 (CP13), sites previously shown to be hyperphosphorylated in AD brain.^[@bib30]^

A*β* treatment of mixed cultures increased tau phosphorylation at both Ser396/404 (*P*\<0.01) and Ser202 (*P*\<0.001) ([Figures 6a and b](#fig6){ref-type="fig"}), when compared with vehicle-treated cultures. In addition to full-length tau, an additional tau species of approximately 50 kDa was labelled with both phosphorylation-specific tau antibodies on blots ([Figure 6a](#fig6){ref-type="fig"}). Co-labelling of blots with antibodies against phosphorylated Ser396 on tau and caspase-3-cleaved tau revealed that the 50 kDa band corresponds to caspase-3-truncated tau ([Figure 6c](#fig6){ref-type="fig"}). This suggests that the generation of caspase-3-cleaved tau in response to elevated A*β* occurs either before or in concert with tau phosphorylation, at least that found at the sites examined here. No increase in tau phosphorylation at either of these epitopes was observed upon A*β* treatment of neuronal cultures. This finding shows that astrocytes are necessary for A*β*-induced tau phosphorylation, at least in this model system. Pretreatment of mixed cultures with minocycline significantly reduced tau phosphorylation at Ser396/404 and Ser202 (*P*\<0.05 for both). Thus, astrocytic inflammatory responses likely have a role in A*β*-induced tau phosphorylation. Furthermore, both astrocyte-mediated tau phosphorylation and the generation of caspase-cleaved tau are closely associated with A*β*-induced neurotoxicity.

The increased release of inflammatory mediators from astrocytes is associated with A*β*-induced neurotoxicity
-------------------------------------------------------------------------------------------------------------

We and others have previously shown that the amounts of specific inflammatory cytokines correlate strongly with pathology development in transgenic mouse models of AD.^[@bib6],\ [@bib8]^ Therefore, the release of inflammatory mediators from A*β*- and minocycline-treated astrocyte-enriched cultures was measured using cytokine arrays. These arrays were chosen as they allow the unbiased and simultaneous measurement of 29 rat cytokines.

A*β* treatment of astrocyte-enriched cultures had a significant overall effect on the release of inflammatory cytokines ([Figure 3a](#fig3){ref-type="fig"}; *P*\<0.01), appearing to elevate the medium amounts of the majority of cytokines studied, including IL-1*β*, IL-6 and IFN-*γ*, each of which has been reported to be increased in response to A*β*.^[@bib11]^ Moreover, additional cytokines, not previously identified, were elevated by A*β*, including IL-13, IL-17 and IP-10. Statistical analysis revealed that cytokine-induced neutrophil chemoattractant (CINC) 2*α*/*β*, IFN-*γ*, IL-1*β*, IL-1ra, IL-6, IL-13, IL-17, IP-10 and monokine induced by IFN-*γ* (MIG) were significantly increased in response to A*β* treatment ([Figures 7a and b](#fig7){ref-type="fig"}; *P*\<0.05 for all). Minocycline pretreatment had a significant overall influence on the A*β*-induced increases in cytokine media amounts ([Figure 3a](#fig3){ref-type="fig"}; *P*\<0.001), with the A*β*-induced increases in the nine aforementioned cytokines being significantly reduced by minocycline pretreatment ([Figures 7a and b](#fig7){ref-type="fig"}; *P*\<0.05 for all). These findings indicate a close association between cytokine release and the neurotoxic events that occur downstream of A*β*, and suggest that suppression of these inflammatory responses may represent a valid therapeutic strategy for the treatment of AD and related neurodegenerative disorders.

Discussion
==========

Here we have used cultured neurons and astrocytes to show that astrocytes have an important role in neurodegenerative events occurring downstream of A*β*. We found that astrocytes exacerbate A*β*-induced neurotoxicity, caspase-3 activation and the generation of caspase-3-cleaved tau fragments, and are necessary for A*β*-induced tau phosphorylation. A soluble factor secreted from astrocytes appears to have an important role in these processes, and we have identified a panel of inflammatory mediators as candidates whose secretion is increased in response to A*β*. Inhibiting astrocytic inflammatory responses with minocycline reduced or abolished these effects of A*β*, suggesting that the soluble factor that has an important role in A*β*-induced toxicity and abnormal tau processing may be an inflammatory cytokine.

Increased LDH release was observed 48 h after A*β* treatment in mixed, but not neuronal cultures, suggesting that astrocytes accelerate the neurotoxic effects of A*β*. These findings are in agreement with those of Paradisi *et al.*,^[@bib31]^ who previously reported that A*β*-treated astrocytes have deleterious effects on neuronal cultures when co-cultured with neurons.^[@bib31]^ In addition, we found that the morphology of astrocytes was altered upon treatment with A*β*, with astrocytes developing convoluted processes and terminal swellings. Specific labelling of dead cells showed that these morphological alterations are not indicative of atrophic cells. Indeed, previous findings indicate that this altered morphological state occurs when astrocytes enter an active, cytokine-secreting state.^[@bib26]^ Furthermore, similar alterations to astrocytic morphology have been reported in 3 × Tg-AD mice in which astrocytes located in close proximity to senile plaques were shown to be hypertrophic, rather than atrophic or dystrophic.^[@bib32]^

We found that A*β*-induced neurotoxicity was associated with increased activity of caspase-3, and that this was exacerbated in the presence of astrocytes. Activated forms of caspase-3 are found in AD brain,^[@bib28]^ and we have previously shown that activation of caspase-3 precedes A*β*-induced neuronal death in primary cortical cultures.^[@bib17]^ The mechanism underlying astrocyte-mediated increased caspase-3 activation in response to A*β* might, therefore, be attributed to factors that are secreted from astrocytes, or direct neuron--astrocyte interactions. Previous evidence suggests that soluble factors released by astrocytes bind to neuronal plasma membrane receptors inducing various cell signalling pathways. For example, when secreted from astrocytes, TNF-*α* binds to neuronal Cd120a/b receptors triggering caspase activation through death effector domains.^[@bib33]^

Astrocytes could potentially influence A*β*-induced neurotoxicity through direct membrane-associated interactions, as described previously.^[@bib27]^ However, by treating neurons with the medium from A*β*-treated astrocyte cultures, we established that a soluble factor(s) secreted from astrocytes accelerates A*β*-induced neuronal toxicity. It is well recognised that the activation of astrocytes is accompanied by increased production of potentially neurotoxic factors, including cytokines, nitric oxide (NO) and reactive oxygen species,^[@bib34]^ and A*β* can induce the production and secretion of IL-1*β*, NO and other inflammatory cytokines in cultured astrocytes and microglia.^[@bib35]^ Here, we took an unbiased approach to show that A*β* treatment significantly increases the secretion of several inflammatory cytokines and chemokines from primary astrocytes, and that minocycline-mediated protection from A*β*-induced neurotoxicity was associated with the decreased secretion of inflammatory mediators from astrocytes. We found that the amounts of CINC2*α*/*β*, IFN-*γ*, IL-1*β*, IL-1ra, IL-6, IL-13, IL-17, IP-10 and MIG in culture medium were significantly increased by A*β*, and these increases were significantly inhibited by the anti-inflammatory agent, minocycline. This suggests that these cytokines, in particular, may have an important role in the neurotoxic events downstream of A*β*.

IL-17 belongs to the same cytokine subfamily as IL-6, acting to induce IL-6 expression in astrocytes.^[@bib13]^ Thus, this finding is in agreement with those of Jana *et al.*,^[@bib11]^ who recently reported that astrocytes induce neuronal death by sphingomyelinase-mediated induction of IL-1*β* and IL-6, together with TNF*α*. Indeed, substantial evidence now indicates that IL-1*β* and IL-6/IL-17 have important roles in the development and/or progression of AD, with these cytokines found in affected brain regions in association with plaques and tangles in AD brain,^[@bib34]^ and transgenic mouse models of AD.^[@bib4],\ [@bib36]^ We also found that increased IP-10 secretion from astrocytes was associated with A*β*-induced neurotoxicity. IP-10 is markedly increased in reactive astrocytes in AD brains, and astrocytes positive for IP-10 are associated with senile plaques.^[@bib37]^ To our knowledge, the findings presented here provide the first evidence for a direct effect of A*β* on IP-10 production and thus may implicate IP-10 in AD pathogenesis.

In addition to A*β*-induced neurotoxicity, we have examined the role of astrocytes in A*β*-induced abnormal tau processing. We found that astrocytes augment A*β*-induced caspase-3 cleavage of tau, in keeping with our previous results.^[@bib17]^ We also describe, for the first time, that astrocytes are required for A*β*-induced tau phosphorylation, at least in this model system. Receptor binding of various cytokines and chemokines leads to the activation of protein kinase C, p38, ERK and JNK mitogen-activated protein kinases and PI3 kinase.^[@bib13]^ Thus, it is possible that astrocyte-derived cytokines bind to neuronal plasma membrane receptors, inducing specific signalling pathways that result in the activation of tau kinases implicated in aberrant tau phosphorylation and cleavage in AD and the tauopathies. For example, binding of secreted IL-1 to neuronal IL-1 receptors leads to the activation of p38 MAPK and tau hyperphosphorylation *in vivo*.^[@bib38]^ Activation of caspase-3 also occurs downstream of IL-1 receptors,^[@bib39]^ which conceivably results in the C-terminal cleavage of tau to generate neurotoxic tau fragments.^[@bib18]^ Our results indicate that it is predominantly the caspase-3-cleaved tau fragments that are more heavily phosphorylated following A*β* treatment of primary cortical cultures, and thus uncovering the mechanism by which astrocytes influence neuronal caspase-3 activity is likely to elucidate the mechanism by which A*β* increases aberrant tau processing, at least in this model system. The mechanism underlying the influence of astrocytes during A*β*-induced tau phosphorylation is currently under investigation in our laboratory.

It is interesting to note, however, that individual cytokines have been reported to have opposing effects on the development of tau and amyloid pathology in transgenic mouse models of AD.^[@bib40]^ Indeed, we have shown previously that several of the cytokines identified here, including IL-17, as being associated with A*β*-associated neurotoxicity, negatively correlated with the amount of tau phosphorylation in htau mice.^[@bib6]^ Thus, further investigation is warranted into the roles of specific inflammatory cytokines in models of AD. Furthermore, it will be important to investigate the findings presented here in intact brain in which the potential influences of microglia--astrocyte signalling and complex neurotransmitter interactions can be investigated in an environment comprising approximately equivalent glia and neurons.

In summary, the results presented here indicate that astrocytes have an important role in mediating the effects of A*β* on cultured neurons. The influence of astrocytes in this system is closely related to the increased secretion of various inflammatory factors, including IL-1*β*, IL-17 and IP-10. Although we cannot rule out the possibility that additional astrocyte-derived soluble factors may have a role in the effects on neurons reported here, these results provide further support for the investigation of anti-inflammatory strategies, or the specific inhibition of selected inflammatory cytokines, as potential therapies for the treatment of AD and related neurodegenerative diseases.

Materials and Methods
=====================

All materials were obtained from Sigma (Poole, Dorset, UK), unless otherwise stated.

Primary cell culture and cell treatments
----------------------------------------

Primary mixed cortical cultures were prepared from embryonic day 18 (E18) rat embryos and cultured as described previously.^[@bib17]^ To establish neuronal cultures, the proliferation of glial cells in mixed cultures was prevented by the addition of 2 *μ*M cytosine arabinoside to three DIV cultures for 48 h. Primary astrocytes were obtained from postnatal day 2 (P2) rats and cultured as described previously.^[@bib41]^ At 2 days before treatment, astrocytes were re-plated into six-well dishes and subsequently maintained in serum-free medium. Cultures were treated with 10 *μ*M soluble oligomeric A*β*~1−42~ (California Peptide Co., Napa, CA, USA) or 20 *μ*M minocycline for 24 h before the addition of A*β* or vehicle (H~2~O). Soluble A*β*~1−42~ was prepared according to the method described in Town *et al.*,^[@bib21]^ which we confirmed generates predominantly soluble oligomeric forms of A*β*.

Toxicity assays
---------------

Cytotoxicity was evaluated by measuring LDH in culture medium using Cytotox 96 assay kits (Promega, Madison, WI, USA) according to the manufacturer\'s directions. After collection of medium, the remaining cells were lysed in 0.9% (w/v) Triton X-100, and LDH content in medium and lysed cells was measured to determine total LDH content. Optical density was measured at 492 nm (Wallac 1420 Victor3 plate reader, Perkin-Elmer, Waltham, MA, USA). LDH release from cells was calculated as a percentage of total LDH in each sample.

Dead cells in culture were identified by a live/dead fixable cell stain (Invitrogen, Paisley, UK) according to the manufacturer\'s instructions. Following uptake of the amine-reactive fluorescent dye provided, cells were washed, fixed and immunolabelled with an antibody against GFAP, as described below.

A*β*~1−42~ ELISA
----------------

Semiquantitative ELISAs were performed as described previously,^[@bib42]^ using the 6E10 antibody (Eurogentec, Southampton, UK) to detect A*β*~1−42~ in culture medium. A*β*~1−42~ standards of known concentration were plated to generate a standard curve from which A*β* content was measured in the medium of primary cortical cultures.

Immunocytochemistry
-------------------

Cultured cells were fixed in 4% (w/v) paraformaldehyde in phosphate-buffered saline (PBS) for 5 min at 37 °C. Following fixation, cells were permeabilised (0.3% (v/v) Triton X-100 in PBS) and blocked with 1% (w/v) bovine serum albumin before incubation with monoclonal antibodies against GFAP (Dako, Ely, UK) or *β*III-tubulin (Cell Signaling, Beverly, MA, USA). Cells were incubated with the appropriate species of secondary antibody and cell nuclei were stained with Hoescht 33342 (5 *μ*g/ml bisbenzimide in PBS). Neurons were examined using a Zeiss Axioskop microscope (Carl Zeiss Inc., Welwyn Garden City, UK). For cell counts, five separate non-overlapping images were taken using the × 20 objective. Cell counts were made using the ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Preparation of neuronal lysates
-------------------------------

After treatments, the medium was removed and cells were washed in ice-cold PBS, followed by lysis in extra strong lysis buffer (100 mM Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS), 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100, 75 mM sodium chloride, 10 mM ethylenediaminetetraacetic acid, 2 mM sodium orthovanadate, 1.25 mM sodium fluoride and protease inhibitor cocktail for mammalian tissues), and centrifugation at 16 000 × *g*~av~ for 20 min at 4 °C. The protein concentration of supernatants was measured using a BCA protein assay kit (Pierce Endogen, Rockford, IL, USA) and samples were standardised to equal protein concentration before being analysed on SDS-PAGE.

SDS-PAGE and Immunoblotting
---------------------------

In total, 5--20 *μ*g protein was separated on 10 or 12% (w/v) SDS-PAGE gels and electrophoretically transferred to nitrocellulose membrane. After blocking with 5% (w/v) non-fat dried milk for 1 h, membranes were probed with primary antibodies, followed by fluorophore-coupled secondary antibodies. Detected proteins were visualised and quantified, using an Odyssey infrared imaging system (Li-Cor Biosciences, Cambridge, UK). The following primary antibodies were used for western blotting. Total tau (rabbit polyclonal; Dako); tau-C3 (tau truncated at Asp421, mouse IgG1; Millipore, Billerica, MA, USA); tau (pSer396) (rabbit polyclonal; Invitrogen Biosource, Carlsbad, CA, USA); cleaved caspase-3 (Asp175, rabbit IgG; Cell Signaling); and *β*-actin (mouse IgG1, clone AC-15; Abcam, Cambridge, UK). The following tau antibodies were kindly gifted by Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA): CP13 (phospho-Ser-202; mouse IgG1) and PHF-1 (phospho-Ser-396/404; mouse IgG1).

Cytokine antibody arrays
------------------------

The medium from astrocyte-enriched cultures was collected and stored at −20 °C pending analysis of pro-inflammatory mediator content using Rat Proteome Profiler antibody arrays (R&D Systems, Minneapolis, MN, USA). Before analysis, samples of medium were thawed on ice and centrifuged at 10 000 × *g*~av~ for 1 min at 4 °C. Media from all experiments were processed in parallel to enable comparisons between experiments. Cytokine and chemokine content was measured according to the manufacturer\'s instructions. Briefly, array membranes were incubated in blocking buffer for 1 h at ambient temperature. Samples of medium were mixed with a cocktail of biotinylated detection antibodies before incubation at 4 °C with the array membranes. Following washing, membranes were incubated with streptavidin--horseradish peroxidase for 30 min at ambient temperature. Immunoreactive species were visualised using enhanced chemoluminescence. Positive and negative controls included in each membrane allowed quantitative analysis by densitometry, with results expressed as percentage change from control cultures.

Statistics
----------

Data were analysed using either Student\'s unpaired *t*-test or one-way analysis of variance (Graphpad Prism 5.0. Software, Graphpad Software Inc., La Jolla, CA, USA), followed by Bonferroni (for grouped) and Newman--Keuls (for all other analyses) *post hoc* tests. Differences were considered statistically significant when *P*\<0.05.

Work in the authors\' laboratories is supported by funding from the Alzheimer\'s Society, Medical Research Council, the Henry Smith Charity and the Wellcome Trust.

AD

:   Alzheimer\'s disease

A*β*

:   *β*-amyloid

CINC

:   cytokine-induced neutrophil chemoattractant

DIV

:   days *in vitro*

ERK

:   extracellular signalling-related kinase

GFAP

:   glial fibrillary acidic protein

IFN

:   interferon

IL

:   interleukin

JNK

:   c-Jun N-terminal kinase

LDH

:   lactate dehydrogenase

MAPK

:   mitogen-activated protein kinase

MIG

:   monokine induced by IFN-*γ*

NO

:   nitric oxide

SDS

:   sodium dodecyl sulphate

TNF

:   tumour necrosis factor

Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by A Verkhratsky

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![Astrocytes accelerate *β*-amyloid (A*β*)-induced neurotoxicity. Bar charts show LDH release from rat primary mixed (black bars) and neuronal (white bars) cultures exposed to 10 *μ*M A*β* for (**a**) 48 or (**b**) 72 h, with and without a 24 h pretreatment with 20 *μ*M minocycline (Min). (**c**) LDH release from rat primary astrocyte cultures exposed to 10 *μ*M A*β* for 72 h, with and without a 24 h pretreatment with 20 *μ*M Min. Values represent LDH release from cells into the medium as a percentage of total LDH, shown as mean±S.E.M. Experiments were performed in triplicate (*N*=9--15). ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001. (**d**) Representative images from mixed cortical cultures treated for 48 h with A*β*, labelled with a dead cell dye (red), and then fixed and immunostained with an antibody against glial fibrillary acidic protein (GFAP) (green). Bisbenzimide was used to stain nuclei (blue). The red dye labels dead cells. Arrows indicate astrocytes that are unaffected by A*β*. Scale bar: 50 *μ*m, *N*=3](cddis201150f1){#fig1}

![*β*-Amyloid (A*β*) induces morphological changes in astrocytes. Representative images from mixed cortical cultures treated for 48 h with (**a**) vehicle, (**b**) 20 *μ*M minocycline, (**c**) 10 *μ*M A*β* or (**d**) 10 *μ*M A*β* with a 24 h pretreatment with 20 *μ*M minocycline. Cells were fixed and immunostained with antibodies against glial fibrillary acidic protein (GFAP) (green), to label astrocytes, or *β*III-tubulin (red), to label neurons. Bisbenzimide was used to stain nuclei (blue). Single arrows indicate astrocytic terminal swellings, and double arrows indicate apoptotic nuclei. Scale bar: 50 *μ*m. *N*=9](cddis201150f2){#fig2}

![A soluble factor secreted from astrocytes mediates *β*-amyloid (A*β*)-induced neuronal death. Bar charts show lactate dehydrogenase (LDH) release into culture medium from rat primary neuronal cultures exposed to (**a**) conditioned medium from primary astrocyte cultures treated with 10 *μ*M A*β* and/or 20 *μ*M Min, and (**b**) cell-free primary astrocyte culture medium infused with 10 *μ*M Ab for 48 h, with and without the addition of 20 *μ*M minocycline (Min). Values are LDH release from cells into medium expressed as a percentage of total LDH, shown as mean±S.E.M. Experiments were performed in triplicate (*N*=9). ^\*^*P*\<0.05; ^\*\*\*^*P*\<0.001](cddis201150f3){#fig3}

![Astrocytes increase *β*-amyloid (A*β*)-induced caspase-3 activity. Western blots of cell lysates from rat primary mixed (M) and neuronal (N) cultures. Cultures were exposed to 10 *μ*M A*β* for 48 h with and without pretreatment with 20 *μ*M minocycline for 24 h. (**a**) Representative western blots probed with an antibody against cleaved caspase-3 (17 and 19 kDa). Blots were also probed with *β*-actin (42 kDa) as a loading control. Molecular weight markers are indicated (kDa). (**b**) Bar chart showing the amount of cleaved caspase-3 following standardisation to *β*-actin in each sample. Data are mean±S.E.M. Experiments were performed in triplicate (*N*=12). ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001](cddis201150f4){#fig4}

![Astrocytes exacerbate *β*-amyloid (A*β*)-induced tau truncation by caspase-3. (**a**) Western blots of cell lysates from rat primary mixed (M) and neuronal (N) cultures. Cultures were exposed to 10 *μ*M A*β* for 48 h with and without pretreatment with 20 *μ*M minocycline for 24 h. Representative western blots probed with an antibody against caspase-3-cleaved tau (50 kDa) are shown. Blots were also probed with *β*-actin (42 kDa) as a loading control. Molecular weight markers are indicated (kDa). (**b**) Bar chart showing the amount of caspase-3-cleaved tau as a proportion of *β*-actin in each sample. (**c**) Representative western blots of cell lysates from primary neuron, astrocyte and mixed cultures, probed with antibodies against total tau (55 kDa) and *β*-actin (42 kDa). Data are mean±S.E.M. Experiments were performed in triplicate (*N*=12). ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001](cddis201150f5){#fig5}

![Astrocytes are necessary for *β*-amyloid (A*β*)-induced tau phosphorylation. Western blots of cell lysates from rat primary mixed (M) and neuronal (N) cultures treated with 10 *μ*M A*β* for 48 h±20 *μ*M minocycline (Min). (**a**) Representative western blots probed with antibodies recognising tau phosphorylated at Ser396/404 (PHF1) and Ser202 (CP13), and total tau. (**b**) Bar chart shows the amount of tau phosphorylated at either Ser396/404 (PHF1) or Ser202 (CP13) as a proportion of total tau. (**c**) Representative western blots of cell lysates from A*β*-treated mixed cultures and neuronal cultures, probed with antibodies recognising tau phosphorylated at Ser396 (green) and caspase-cleaved tau (red). Molecular weight markers are indicated (kDa). Data are mean±S.E.M. Experiments were performed in triplicate (*N*=12). ^\*^*P*\<0.05; ^\*\*^*P*\<0.01; ^\*\*\*^*P*\<0.001](cddis201150f6){#fig6}

![*β*-Amyloid (A*β*) treatment increases the release of several inflammatory mediators from astrocytes. Astrocyte cultures were treated with 10 *μ*M A*β* for 48 h with and without pretreatment with 20 *μ*M minocycline (Min). Cytokine arrays were used to detect the amounts of 29 inflammatory mediators in the medium of treated cells. (**a**) Bar chart shows quantification of medium cytokine amounts in arbitrary densitometry units (a.u.). (**b**) Bar chart shows percentage change in the media amounts of those cytokines significantly influenced by A*β* and/or minocycline as percentage change from control. Values represent mean±S.E.M., *n*=3. ^\*^*P*\<0.05 when compared with control; ^\#^*P*\<0.05 compared with A*β* treated](cddis201150f7){#fig7}
